Restrictions in use of cyproterone acetate due to risk of meningioma

Table of contents

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Key facts

Active substance
cyproterone
Therapeutic area (MeSH)
Androgen Antagonists
Procedure number
EMEA/H/A-31/1488
Regulatory outcome
Variation
DHPC type
Referral - Article 31
Referral name
Cyproterone-containing medicinal products

How useful was this page?

Add your rating